Callejas-Moraga EL, Guillén- Del-Castillo A, Perurena-Prieto J, et al. - Researchers analyzed Systemic Sclerosis (SSc) patients, who express anti- U11/U12 RNP (RNPC-3) antibodies, in order to determine prevalence, clinical features, as well as overall survival and event-free survival (EFS) in this patient population. Presence of anti-RNPC-3 antibodies was evident in 19 of 447 (4.3%) patients, and people with anti-RNPC-3 antibodies more frequently had interstitial lung disease (ILD). Factors that were independently related to worse EFS in a multivariate Cox regression analysis were: diffuse cutaneous subtype, age at onset, the presence of ILD or pulmonary arterial hypertension, and the expression of anti-RNPC-3 positivity or anti-topoisomerase I. Findings demonstrated a higher frequency of ILD and either end-stage lung disease or death in relation to the presence of anti-RNPC-3. Based on findings, anti-RNPC-3 represents an independent poor prognosis antibody in SSc, particularly in the presence of ILD.